Manufacturing Pharmacy

Research and Development / Refurbishment

Key Features:

- Refurbishment to MHRA compliance levels
- Works adjacent to operational laboratories
- A challenging, phased construction programme

This facility holds a manufacturer's 'specials' licence, an investigational medicinal products (IMP) licence and a wholesale dealer's licence and are able to develop and distribute a wide range of products.

Refurbishment was required for the current manufacturing pharmacy to create state-of-the-art facilities for the hospital and included the remodelling of the existing manufacturing pharmacy Aseptic and Civas suites to provide a facility which achieves MHRA compliance.

Works include the strip out and demolition of the existing facilities, new walls, ceiling and floor finishes together with specialist pass through hatches and laboratory furniture. Services need to meet specific air pressure regimes to ensure that parts of the facility are maintained under positive pressure to avoid cross contamination of product.

The refurbishment comprises of three separate phases running concurrently: Non-sterile production, civas and the quality control laboratory. Initially, the quality control lab and quarantine room had to be re-sited as part of enabling works.

Working adjacent to operational laboratories

In order to ensure minimal disruption, the Manufacturing Pharmacy continued to operate the drug production area (Cytos Lab), whilst an extensive refurbishment of facilities was undertaken in the adjacent area.

Crucially all M&E services to the Cytos area remained fully operational, to ensure that drop in air pressure did not occur which would result in a loss of up to 30 days in drug production.

Close client liaison was essential, particularly, communication with senior members of the department with regards to the shutdown of any services.

Client:	Royal Free London NHS Foundation Trust
Project Value:	£1,700,000
Programme Duration:	26 weeks
Architect:	AHP Architects
Quantity Surveyor:	AECOM